NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia

mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia

(2012) Rafal T. Olszewski et al.   SCHIZOPHRENIA RESEARCH

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

(2011) Bruce J. Kinon et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family

(2011) Joseph H. Neale et al.   JOURNAL OF NEUROCHEMISTRY

N-Acetylaspartylglutamate is an agonist at mGluR3 in vivo and in vitro

(2011) Joseph H. Neale   JOURNAL OF NEUROCHEMISTRY

The Role of 5-Hydroxytryptamine 7 Receptors in the Phencyclidine-Induced Novel Object Recognition Deficit in Rats

(2011) M. Horiguchi et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Inside the minds of mice and men

(2011) Monya Baker   NATURE

Declarative memory deficits and schizophrenia: Problems and prospects

(2011) William S. Stone et al.   NEUROBIOLOGY OF LEARNING AND MEMORY

Effects of olanzapine, sertindole and clozapine on MK-801 induced visual memory deficits in mice

(2011) Oguz Mutlu et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and d-amphetamine models of schizophrenia

(2011) Caterina P. Profaci et al.   PSYCHOPHARMACOLOGY

Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models

(2011) L. Lyon et al.   PSYCHOPHARMACOLOGY

Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats

(2011) Masakuni Horiguchi et al.   PSYCHOPHARMACOLOGY

The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment

(2011) Herbert Y. Meltzer et al.   PSYCHOPHARMACOLOGY

Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease

(2010) Colleen M. Niswender et al.   Annual Review of Pharmacology and Toxicology

Disruption of Performance in the Five-Choice Serial Reaction Time Task Induced By Administration of N-Methyl-D-Aspartate Receptor Antagonists: Relevance to Cognitive Dysfunction in Schizophrenia

(2010) Nurith Amitai et al.   BIOLOGICAL PSYCHIATRY

Mouse behavioral endophenotypes for schizophrenia

(2010) Laura C. Amann et al.   BRAIN RESEARCH BULLETIN

Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists

(2010) John H. Krystal et al.   CNS DRUGS

Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition

(2010) Gerard J. Marek   EUROPEAN JOURNAL OF PHARMACOLOGY

The difference in effect of mGlu2/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801

(2010) Karel Vales et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Progress and prospects: stem cells and neurological diseases

(2010) S Gögel et al.   GENE THERAPY

Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential

(2010) Karen J. Gregory et al.   NEUROPHARMACOLOGY

Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism

(2010) Shikha Snigdha et al.   PSYCHOPHARMACOLOGY

The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat

(2010) Caitlin A. Jones et al.   PSYCHOPHARMACOLOGY

Differential Expression of Metabotropic Glutamate Receptors 2 and 3 in Schizophrenia: A Mechanism for Antipsychotic Drug Action?

(2009) Subroto Ghose et al.   AMERICAN JOURNAL OF PSYCHIATRY

Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition

(2009) Chantal Schlumberger et al.   BEHAVIOURAL PHARMACOLOGY

Learning and Generalization in Schizophrenia: Effects of Disease and Antipsychotic Drug Treatment

(2009) Daphna Shohamy et al.   BIOLOGICAL PSYCHIATRY

Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495

(2009) A.-M. Linden et al.   NEUROPHARMACOLOGY

Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia

(2009) Subroto Ghose et al.   SCHIZOPHRENIA RESEARCH

Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039)

(2008) M. J. Fell et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Review: The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia

(2008) PJ Harrison et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Expression of a GRM3 Splice Variant is Increased in the Dorsolateral Prefrontal Cortex of Individuals Carrying a Schizophrenia Risk SNP

(2008) Leah J Sartorius et al.   NEUROPSYCHOPHARMACOLOGY

Phencyclidine and Dizocilpine Induced Behaviors Reduced by N-acetylaspartylglutamate Peptidase Inhibition via Metabotropic Glutamate Receptors

(2007) Rafal T. Olszewski et al.   BIOLOGICAL PSYCHIATRY